XGN News and Press, Exagen Inc. From 03/20/23

2023-03-20 16:10:12 ET Exagen press release ( NASDAQ: XGN ): Q4 GAAP EPS of -$0.83 misses by $0.07 . Revenue of $12.84M (+1.2% Y/Y) beats by $4.14M . Record 135,210 flagship AVISE® CTD tests, for the full year 2022, including 33,819 tests for the fourth qu...

SAN DIEGO, March 20, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights: Record 135,210 flagship AVISE® C...

SAN DIEGO, March 06, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter and year ended December 31, 2022, after the market close on Monday, March 20, 2023. John Aballi, Exagen’s Pr...

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following March investor conferences. Cowen 43 rd Annual Health Care Conference ...

SAN DIEGO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 14-16, 2023 in Sn...

SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Tina S. Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Directors, effective January 19, 2023. Dr. Nova succeeds Brian Birk,...

Exagen ( NASDAQ: XGN ) stock climbed 47% on Tuesday after the commercial-stage diagnostics firm raised its 2022 revenue guidance and posted stronger-than-expected Q3 results . The company now expects 2022 revenue of $40M-$43M vs. prior outlook of $35M-$40M, reflectin...

Exagen Inc. (XGN) Q3 2022 Earnings Conference Call November 14, 2022 04:30 PM ET Company Participants Ryan Douglas - IR John Aballi - President and CEO Kamal Adawi - CFO Mark Hazeltine - Chief Operating Officer Conference Call Participants Max Mas...

Exagen press release ( NASDAQ: XGN ): Q3 GAAP EPS of -$0.47 beats by $0.29 . Revenue of $14.7M (+20.0% Y/Y) beats by $5.57M . For the full year 2022, the company is increasing its revenue guidance range to $40 million to $43 million. Consensus is $38.10M. ...

SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2022. Third Quarter Highlights: Total revenue of $14.7 million recognized in ...